This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, June 25, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that its Chairman and CEO, Dr. Robin L. Smith, will give a company presentation at the 5
th annual OneMedForum New York on Thursday, June 27, at 8 AM EDT at The Metropolitan Club.
Dr. Robin L. Smith was recently named a finalist for the Ernst & Young Entrepreneur Of The Year® 2013 Award in the New York region by Ernst & Young LLP. The awards program recognizes high-growth entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. The finalists were selected by a panel of independent judges. "I am honored to have been recognized by Ernst & Young LLP for my accomplishments, but believe success can only come about by assembling a dynamic, experienced and nimble management team with a proven track record of success," said Dr. Robin L. Smith, Chairman and CEO of NeoStem.
Over the past 7 years, Dr. Smith has focused on building NeoStem, a company at the forefront of a paradigm shift underway in medicine toward cell therapy – a shift away from treating disease with drugs and toward treating disease with our own cells; a shift away from treating symptoms and toward cures for the illnesses that cause the most suffering; a shift away from chemical drug development and toward looking inside ourselves to understand and then amplify our body's natural repair mechanisms. NeoStem's leadership in cell therapy is occurring through its vertically integrating the collection, storage and processing of cellular material and by developing, manufacturing, distributing, and delivering cell therapy products.
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.